Literature DB >> 10375199

Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones.

M A Birch1, T M Skerry.   

Abstract

Bone cells are regulated by interactions with both growth factors and components of the extracellular matrix (ECM). Syndecans are cell-surface heparan sulfate proteoglycans known to play a role in cell adhesion and migration, and binding of growth factors. This study was performed to investigate the expression of syndecans by osteoblasts. Reverse transcription-linked polymerase chain reaction (RT-PCR) and Northern analysis detected syndecan transcripts in the human osteosarcoma cell lines MG-63, TE-85, SaOS-2, and U2OS; human osteoblast-like cells; rat calvarial osteoblasts; and in human bone. Western blot analysis of proteoglycans from MG-63 and TE-85 cells detected multiple heparan sulfate proteoglycan core proteins consistent with syndecan expression. Regulation of syndecan-1, -2, and -4 expression was investigated in TE-85, MG-63, and SaOS-2 cells, in response to interleukin (IL)-1beta, and IL-6, parathyroid hormone [PTH(1-34)], and 1,25(OH)2-vitamin D3. Northern analysis demonstrated that in the osteosarcoma cell lines there was no regulation of syndecan transcript levels in response to PTH(1-34) or 1,25(OH)2-vitamin D3 for 24 or 48 h. In contrast, when MG-63 and SaOS-2 cells were incubated with IL-1beta (0.01-10 ng/mL) and IL-6 (0.1-50 ng/mL) there was a dose-dependent decrease in mRNA levels for syndecan-1 and -2 at 24 and 48 h, but in response to IL-1beta upregulation in the levels of syndecan-4 transcripts. In addition, Northern analysis was performed on RNA isolated from neonatal rat calvarial osteoblasts cultured under conditions that promote osteogenesis for 0, 5, 13, 21, and 35 days. Syndecan-1 expression was observed to decrease during the culture period, syndecan-2 transcript levels increased, and there appeared to be no overall change in syndecan-4 levels. Controlled expression of syndecans by cells of the osteoblast lineage may be important in the regulation of osteoblastic proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375199     DOI: 10.1016/s8756-3282(99)00088-5

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

1.  Finding genes in the C2C12 osteogenic pathway by k-nearest-neighbor classification of expression data.

Authors:  Joachim Theilhaber; Timothy Connolly; Sergio Roman-Roman; Steven Bushnell; Amanda Jackson; Kathy Call; Teresa Garcia; Roland Baron
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

2.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

Review 3.  Role of syndecan-2 in osteoblast biology and pathology.

Authors:  Rafik Mansouri; Eric Haÿ; Pierre J Marie; Dominique Modrowski
Journal:  Bonekey Rep       Date:  2015-04-01

4.  Simultaneous gene expression analysis of steady-state and actively translated mRNA populations from osteosarcoma MG-63 cells in response to IL-1alpha via an open expression analysis platform.

Authors:  Jingfang Ju; Chunli Huang; Stacey A Minskoff; Jane E Mayotte; Bruce E Taillon; Jan F Simons
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

Review 5.  Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.

Authors:  Jessica Oyie Sousa Onyeisi; Carla Cristina Lopes; Martin Götte
Journal:  Biomolecules       Date:  2021-03-26

6.  Dose dependent effects of platelet derived chondroitinsulfate A on the binding of CCL5 to endothelial cells.

Authors:  Christian Weingart; Peter J Nelson; Bernhard K Krämer; Matthias Mack
Journal:  BMC Immunol       Date:  2008-12-10       Impact factor: 3.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.